Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesCognitive, LongevityPinealon

Pinealon

/ Synthetic tetrapeptide; Khavinson-tradition pineal bioregulator; sequence shared with Epitalon
SPECULATIVEN = 0 · TESTING PENDINGMW 388.00 g·mol⁻¹

ALIAS · Ala-Glu-Asp-Gly · AEDG · Pineal bioregulator (Khavinson)

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequenceAEDG (Ala-Glu-Asp-Gly)
MW · 388.00CLASS · Synthetic tetrapeptide; Khavinson-tradition pineal bioregulator; sequence shared with EpitalonCATEGORY · Cognitive, Longevity

Tier 4. Russian-origin literature from the Khavinson peptide-bioregulator tradition, primarily from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology and collaborators. The published amino-acid sequence (AEDG) is identical to Epitalon — vendor product nomenclature varies, and some sources distinguish Pinealon from Epitalon by salt form or preparation rather than by sequence. No Western independent replication of the principal claims; no Phase 2/3 trials by Western regulatory standards.

§ B · Mechanism of action

The proposed mechanism in the Khavinson literature is direct DNA binding by the short tetrapeptide to specific gene-promoter regions, with downstream effects on telomerase expression, pineal melatonin synthesis, and age-related gene-expression patterns. The mechanism is not established by independent Western pharmacology; the molecular basis for sequence-specific DNA binding by an unmodified tetrapeptide is not consistent with mainstream nucleic-acid biochemistry, and the claims have not been independently replicated.

§ C · Human clinical evidence

Tier 4. Russian-language and Russian-origin English-language publications report effects on rodent lifespan, melatonin rhythms, and cognitive measures in aging models. Primary research output concentrated in journals associated with the Khavinson group; independent Western replication is essentially absent.

§ D · Primary literature
PubMed25826983Khavinson VKh et al.Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data · Advances in Gerontology · reviewReview from the Khavinson group (in Russian) covering the pineal bioregulator peptide programme including AEDG (Pinealon / Epitalon), arguing for telomerase modulation and age-marker effects.Limitations: Authored by the originating research tradition; published in a Russian-language journal; not independently replicated by Western groups.2014
§ F · Safety signal

No formal Western safety database. The Khavinson literature reports no significant toxicity in rodent studies at the doses used; this does not substitute for a structured Phase 1 evaluation.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

The principal gaps are nomenclature confusion with Epitalon (same AEDG sequence; vendor branding and salt-form differences are inconsistent across suppliers), single-tradition dominance (Khavinson group), and the absence of independent Western replication for the foundational telomerase and lifespan claims. Vendor-sold Pinealon and Epitalon material is rarely characterised as to identity, purity, or sterility to clinical-grade standards. The Open Assay Epitalon page covers the same sequence and contains the relevant literature in greater depth.